- This event has passed.
Biopharma R&D During COVID-19: One Year Later
The SARS-CoV-2 pandemic brought new challenges and opportunities to biotech and pharmaceutical companies. Several new vaccines and therapies have already been brought to patients. Companies initiated efforts to catalyze collaborative research, new ways of working and social justice. One year into the pandemic, we will examine the initial lessons for biopharma R&D – what worked, what didn’t, and how can the industry sustain momentum on emerging priorities for the future? Join Harvard Medical School Executive Education for a discussion with three of the industry’s top leaders.
Jay Bradner, MD
President, Novartis Institutes for BioMedical Research (NIBR)
Executive Committee Member, Novartis
Andrew Plump, MD, PhD
President, Research & Development, Takeda Pharmaceuticals
Michelle McMurry-Heath, MD, PhD
President & CEO, Biotechnology Innovation Organization (BIO)
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.